Table 2.
Antibiotic resistance of invasive P. aeruginosa
| Countrya | No. of isolates | No. of isolates (%) non-susceptible to | MDR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Aminoglycoside | Carbapenem | Cephalosporin | Fluoroquinolone | β-lactamase inhibitor | Monobactam | ||||
| Amikacin | Gentamicin | Meropenem | Cefepime | Levofloxacin | Piperacillin-tazobactam | Aztreonam | |||
| USAb | 116 | 0 (0) | 10 (8.6) | 23 (19.8) | 10 (8.6) | 48 (41.4) | 24 (21.0) | 56 (48.3) | 28 (24.1) |
| USAc | 51 | 0 (0) | 7 (14.0) | 9 (17.6) | 5 (10.0) | 21 (41.2) | 13 (25.5) | 27 (53.0) | 14 (27.4) |
| Denmark | 35 | 2 (5.7) | 2 (5.7) | 6 (17.1) | 5 (14.3) | 20 (57.1) | 5 (14.3) | 27 (77.1) | 8 (22.8) |
| Sweden | 25 | 2 (8.0) | 2 (8.0) | 4 (16.0) | 2 (8.0) | 9 (36.0) | 3 (12.0) | 6 (24.0) | 5 (20.0) |
| South Africa | 50 | 8 (16.0) | 15 (30.0) | 18 (36.0) | 17 (34.0) | 25 (50.0) | 15 (30.0) | 42 (84.0) | 20 (40.0) |
| Mali | 24 | 1 (4.2) | 1 (4.2) | 0 (0) | 0 (0) | 1 (4.2) | 0 (0) | 8 (33.3) | 0 (0) |
| DR Congo | 3 | 0 (0) | 2 (66.7) | 1 (33.3) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 2 (66.7) | 2 (66.7) |
| Japan | 14 | 0 (0) | 0 (0) | 4 (28.6) | 0 (0) | 4 (28.6) | 0 (0) | 7 (50.0) | 2 (14.3) |
| Singapore | 25 | 2 (8.0) | 7 (28.0) | 9 (36.0) | 9 (36.0) | 12 (48.0) | 10 (40.0) | 16 (64.0) | 11 (44.0) |
| Pakistan | 27 | 6 (22.2) | 6 (22.2) | 8 (29.6) | 8 (29.6) | 14 (51.8) | 9 (33.3) | 15 (55.5) | 9 (33.3) |
| Overall | 370 | 21 (5.7) | 52 (14.0) | 82 (22.2) | 57 (15.4) | 156 (42.2) | 81 (22.0) | 206 (55.7) | 99 (26.7) |
aIsolates collected from Greece were excluded
bIsolates were obtained from University of Maryland Medical Center
cIsolates were obtained from Duke University Medical Center